Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy.

Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy.
复制标题

DOI:
10.1016/j.urolonc.2013.08.006
复制
发表时间:
2014-08
期刊:
Urologic oncology
影响因子:
--
通讯作者:
Marks LS
Marks LS
中科院分区:
其他
文献类型:
--
作者:
Sonn GA;Margolis DJ;Marks LS

文献摘要

参考文献

被引文献

相似文献

多参数磁共振成像(MRI)的最新进展使图像引导检测前列腺癌成为可能。MRI与实时超声(US)的融合允许来自MRI的信息用于在基于办公室的程序中在US引导下引导活检针。融合可以使用融合设备以认知方式或电子方式进行。融合器械允许将存储的MRI图像叠加(共配准)到实时US图像上; MRI上发现的可疑区域可以作为US引导活检期间的目标。目前可用的融合设备使用多种技术来执行配准:通过带有内置编码器的机械臂进行机器人跟踪(Artemis/Eigen,BioJet/Geoscan);电磁跟踪(UroNav/Philips-Invivo,Hi-RVS/Hitachi);或使用3D US探头进行跟踪(Urostation/Koelis)。靶向融合活检已被证明比常规活检识别更多临床显著癌症和更少不显著癌症。融合活检似乎是传统活检的一个重大进步,因为它允许(1)直接靶向超声上看不到的可疑区域,(2)对接受主动监测的男性的特定癌性部位进行随访活检。
Recent advances in multiparametric magnetic resonance imaging (MRI) have enabled image-guided detection of prostate cancer. Fusion of MRI with real-time ultrasound (US) allows the information from MRI to be used to direct biopsy needles under US guidance in an office-based procedure. Fusion can be performed either cognitively or electronically, using a fusion device. Fusion devices allow superimposition (coregistration) of stored MRI images on real-time US images; areas of suspicion found on MRI can then serve as targets during US-guided biopsy. Currently available fusion devices use a variety of technologies to perform coregistration: robotic tracking via a mechanical arm with built-in encoders (Artemis/Eigen, BioJet/Geoscan); electromagnetic tracking (UroNav/Philips-Invivo, Hi-RVS/Hitachi); or tracking with a 3D US probe (Urostation/Koelis). Targeted fusion biopsy has been shown to identify more clinically significant cancers and fewer insignificant cancers than conventional biopsy. Fusion biopsy appears to be a major advancement over conventional biopsy because it allows (1) direct targeting of suspicious areas not seen on US and (2) follow-up biopsy of specific cancerous sites in men undergoing active surveillance.
DOI: 10.1016/j.urolonc.2011.02.014
发表时间: 2011-05
期刊: Urologic oncology
影响因子: --
作者:
Natarajan S;Marks LS;Margolis DJ;Huang J;Macairan ML;Lieu P;Fenster A
通讯作者: Fenster A
DOI: 10.1097/mou.0b013e32835ad3ee
发表时间: 2013-01
影响因子: 2.5
作者:
Marks L;Young S;Natarajan S
通讯作者: Natarajan S
DOI: 10.1016/j.ijrobp.2004.09.023
发表时间: 2005-01-01
影响因子: 7
作者:
Deurloo, KEI;Steenbakkers, RJHM;van Herk, M
通讯作者: van Herk, M
DOI: 10.7863/jum.2009.28.11.1561
发表时间: 2009-11-01
影响因子: 2.3
作者:
Guo, Yujun;Werahera, Priya N.;Suri, Jasjit S.
通讯作者: Suri, Jasjit S.